Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CytoMed Therapeutics Limited Ordinary Shares
GDTC | US
2.22
USD0
0%
GDTC | US
About CytoMed Therapeutics Limited Ordinary Shares
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/03/2024
As of date
21/10/2024
Close
2.22
Open
2.12
High
2.23
Low
2.12
CytoMed Therapeutics Limited a pre-clinical biopharmaceutical company focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT which utilizes iPSC as a starting material to generate gdNKT a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
View LessGDTC | US
Risk
63.2
Sharpe
-0.50
Luna's Score
46/100
Recommendation
Hold
Luna says (GDTC | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
63.4%1 month
63.2%3 months
77.5%6 months
71.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.31
Debt to equity
0.04
Debt to assets
0.04
Ent. to EBITDA
-4.45
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-3.12M
MarketCap
25.62M
MarketCap(USD)
25.62M
Div. yield
-
Op. margin
-735.97
Erngs. growth
-
Rev. growth
-21.10
Ret. on equity
-26.26
Short ratio
40.28
Short perc.
6.97
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.34
Range1M
1.04
Range3M
1.06
Volumes: Market Activity
Rel. volume
1.08
Price X volume
32.07K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.45 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.31 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 77.48 | 72.80 | Par |
| Debt to Equity | 0.04 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 25.62M | 3.66B | Emerging |
